The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development

References

1. Acharya I. L., Lowe C. U., Thaps R., Gurubacharya V. L., Shresta M. B., Cadoz M., Schulz D., Armand J., Bryla D. A., Trollfors B., Cramton T., Schneerson R., Robbins J. B. Prevention of typhoid fever in Nepal with the Vi polysaccharide of Salmonella typhi, A preliminary report.. New Engl J Med 1987; 3171101–1109
   [Google Scholar]
2. Ahren C., Wenneras C., Holmgren J., Svennerholm A. Intestinal antibody response after oral immunisation with a prototype cholera B subunit-colonisation factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine 1993; 9929–934
   [Google Scholar]
3. Bacon G. A., Burrows T. W., Yates M. The effects of biochemical mutations on the virulence of bacterium typhosa\ the virulence of mutants. Br J Exp Pathol 1950; 31703–711
   [Google Scholar]
4. Benjamin W. H., Hall P., Briles D. E. A hem A mutation renders Salmonella typhimurium avirulent in mice, yet capable of eliciting protection against intravenous infection with Styphi-murium. Microb Pathog 1991; 11289–296
   [Google Scholar]
5. Bienenstock J., McDermott M., Befus D., O′Neil L. M. A common mucosal immunological system involving the bronchus, breast and bowel. Adv Exp Med Biol 1978; 10753–69
   [Google Scholar]
6. Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis 1987; 1551260–1265
   [Google Scholar]
7. Bliska J. B., Galan J. E., Falkow S. Signal transduction in the mammalian cell during bacterial attachment and entry. Cell 1993; 73903–920
   [Google Scholar]
8. Bowe F., O′Goara P., Maskell D., Cafferkey M., Dougan G. In vivo properties of Yersinia enterocolitica aroA mutants. Infect Immun 1989; 573234–3236
   [Google Scholar]
9. Bromander A. J., Holmgren J., Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immun 1991; 1462908–2914
   [Google Scholar]
10. Brown A., Hormaeche C. E., Demarco de Hormaeche R., Winther W., Dougan G., Maskell D., Stocker B. A. D. Attenuated aroA 3,typhimurium vaccine elicits humoral and cellular immunity to cloned beta-galactosidase in mice. J Infect Dis 1986; 15586–92
    [Google Scholar]
11. Chamberlain L., Strugnell R., Dougan G., Hormaeche C. E., Demarco de Hormaeche R. Neisseria gonorrhoeae strain MS11 harbouring a mutation in gene aroA is attenuated and immunogenic. Microb Pathog 1993; 1551–63
    [Google Scholar]
12. Charles I., Dougan G. Gene expression and the development of live enteric vaccines. Trends Biotechnol 1990; 8117–121
    [Google Scholar]
13. Charles I., Dougan G., Pickard D., Chatfield S. N., Smith M., Novotny P., Morrissey P. M., Fairweather N. F. Molecular cloning and characterisation of P. 69, a protective outer membrane protein from Bordetella pertussis. Proc Natl Acad Sei USA 1988; 893554–3558
    [Google Scholar]
14. Charles I. G., Lamb H. K., Pickard D., Dougan G., Hawkins A. Isolation, characterization and nucleotide sequencing of the aroC genes encoding chorismate synthase from Salmonella typhi and Escherichia coli. J Gen Microbiol 1990a; 136353–358
    [Google Scholar]
15. Charles I. G., Li J. L., Dougan G., Pickard D., Francis M., Romanos M., Beesley K., Brennan M., Mandark C. R., Jensen M., Heron I., Chubb A., Novotny P., Fairweather N. F. Identification of an immunodominant region of the protective protein P. 69 from Bordetella pertussis. Eur J Immunol 1990b; 211147–1153
    [Google Scholar]
16. Chatfield S. N., Dougan G., Charles I. Complete nucleotide sequence of the aroA gene from Salmonella typhi encoding 5-enolpyruvyl-shikimate 3-phosphate synthase. Nucleic Acids Res 1990; 186133
    [Google Scholar]
17. Chatfield S. N., Dorman C. J., Hayward C., Dougan G. The role of owpR-dependent genes in Salmonella typhimurium virulence: mutants deficient in both ompC and ompF are attenuated in vivo. Infect Immun 1991; 59449–452
    [Google Scholar]
18. Chatfield S. N., Fairweather N., Charles I., Pickard D., Levine M., Hone D., Posada M., Strugnell R. A., Dougan G. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine 1992a; 1053–60
    [Google Scholar]
19. Chatfield S. N., Strachan K., Pickard D., Charles I. G., Hormaeche C. E., Dougan G. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microb Pathog 1992b; 12145–151
    [Google Scholar]
20. Chatfield S. N., Charles I. G., Makoff A. J., Oxer M. D., Dougan G., Pickard D., Slater D., Fairweather N. F. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a singledose oral tetanus vaccine. Bio /Technology 1992c; 10888–892
    [Google Scholar]
21. Clements J. D., Lyon F. L., Lowe K. L., Farrand A. L., El-Morshidy S. Oral immunization of mice with attenuated Salmonella enteritidis containing a recombinant plasmid which codes for production of the B-subunit of heat-labile enterotoxin of Escherichia coli. Infect Immun 1986; 53685–693
    [Google Scholar]
22. Collins F. M. Vaccines and cell-mediated immunity. Bacteriol Rev 1974; 38371–402
    [Google Scholar]
23. Curtiss R. R., Kelly S. M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclase receptor protein are avirulent and immunogenic. Infect Immun 1987; 553035–3043
    [Google Scholar]
24. Curtiss R. Ill, Kelly S. M., Gulig P. A., Nakayama K. Selective delivery of antigens by recombinant bacteria. Curr Top Microbiol Immunol 1989; 14635–54
    [Google Scholar]
25. Dorman C. J., Chatfield S. N., Higgins C. H., Hayward C., Dougan G. Characterization of porin and ompR mutants of a virulent strain of Salmonella typhimurium-omp mutants are attenuated in vivo. Infect Immun 1989; 572136–2140
    [Google Scholar]
26. Dougan G. Molecular approaches to the characterization of bacterial virulence determinants. J Gen Microbiol 1989; 1351397–1406
    [Google Scholar]
27. Dougan G., Masked D., Pickard D., Hormaeche C. Isolation of stable aroA mutants of Salmonella typhi Ty2: properties and preliminary characterization. Mol & Gen Genet 1986; 207402–405
    [Google Scholar]
28. Dougan G., Chatfield S. N., Pickard D., O’Callaghan D., Masked D. Construction and characterization of Salmonella vaccine strains harbouring mutations in two different aro genes. J Infect Dis 1988; 1581329–1335
    [Google Scholar]
29. Edelman R., Levine M. M. Summary of an international meeting on typhoid fever. Rev Infect Dis 1986; 8329–340
    [Google Scholar]
30. Elson C. J., Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 1984; 1322736–2743
    [Google Scholar]
31. Fairweather N. F., Lyness V., Masked D. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun 1987; 552541–2545
    [Google Scholar]
32. Fairweather N. F., Chatfield S. N., Makoff A. J., Strugnell R. A., Bester J., Masked D. J., Dougan G. Oral vaccination against tetanus using a live, rationally attenuated Salmonella carrier. Infect Immun 1990; 581323–1329
    [Google Scholar]
33. Fields P. I., Swanson R. V., Heidaris C. G., Heffron F. Mutants of Salmonella typhimurium that cannot survive inside macrophages are avirulent. Proc Natl Acad Sei USA 1986; 835189–5193
    [Google Scholar]
34. Finlay B. B., Falkow S. Common themes in microbial pathogenicity. Microbiol Rev 1989; 53210–230
    [Google Scholar]
35. Finlay B. B., Starnbach M. N., Francis C., Stocker B. A. D., Chatfield S. N., Dougan G., Falkow S. Identification and characterization of TnphoA mutants of Salmonella which are unable to penetrate through a polarized MDCK epithelial cell monolayer. Mol Microbiol 1988; 2757–766
    [Google Scholar]
36. Fu Z. F., Rupprecht C. E., Dietzshold B., Saikumar P., Niu H. S., Babka I., Wunner W. H., Koprowski H. Oral vaccination of racoons (Procyon lotor) with baculovirus expressed rabies virus glycoprotein. Vaccine 1993; 11925–928
    [Google Scholar]
37. Germanier R., Furer E. Immunity in experimental salmonellosis II. Basis for the avirulence and protective capacity of galE mutants of Salmonella typhimurium. . Infect Immun 1971; 4663–672
    [Google Scholar]
38. Germanier R., Furer E. Isolation and characterization of a galE mutant Ty21a of Salmonella typhi-, a candidate strain for a live oral typhoid vaccine. J Infect Dis 1975; 131553–558
    [Google Scholar]
39. Hoiseth S. K., Stocker B. A. D. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981; 291238–239
    [Google Scholar]
40. Holmgren J., Czerkinsky C. Cholera as a model for research on mucosal immunity and development of oral vaccines. Curr Opin Immunol 1992; 4387–392
    [Google Scholar]
41. Hone D., Morona R., Attridge S., Hackett J. Construction of a defined galE mutant of Salmonella for vaccine use. J Infect Dis 1987; 156167–174
    [Google Scholar]
42. Hone D., Attridge S., van den Bosch L., Hackett J. A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains. Microb Pathog 1988a; 5407–418
    [Google Scholar]
43. Hone D. M., Attridge S. R., Forrest B., Morrona R., Daniels D., LaBrooy J. T., Bartholemews R. C. A., Shearman D. J. C., Hackett J. A galE (Vi antigen negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun 1988b; 561326–1333
    [Google Scholar]
44. Hone D. M., Harris A., Chatfield S. N., Dougan G., Levine M. M. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 1991; 9810–816
    [Google Scholar]
45. Hormaeche C. E. Natural resistance to Salmonella typhimurium in mice. Immunology 1979; 37311–318
    [Google Scholar]
46. Johnson K. J., Charles I. G., Miller I. A., Pickard D., O’Goara P., Costa G., Ali T., Hormaeche C. E. The role of a stress- response protein in Salmonella typhimurium virulence. Mol Microbiol 1991; 5401–407
    [Google Scholar]
47. Jones P. W., Dougan G., Hayward C., Mackenzie N., Collins P., Chatfield S. N. Oral vaccination of calves against experimental salmonellosis using a double aro mutant of Salmonella typhimurium. Vaccine 1990; 929–34
    [Google Scholar]
48. Karnell A., Cam P. D., Verma N., Lindberg A. A. aroD deletion attenuates Shigalla flexneri strain 2457T and makes it a safe and efficatious oral vaccine in monkeys. Vaccine 1993; 11830–836
    [Google Scholar]
49. Levine M. M., Hone D. M. New and improved vaccines against typhoid fever. In New Generation Vaccines 1992 pp. 269–283 New York: Marcel Dekker;
    [Google Scholar]
50. Levine M. M., Kaper J. B., Black R. E., Clements M. L. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rep 1983; 47510–540
    [Google Scholar]
51. Levine M. M., Ferreccio C., Black R. E., Germanier R. Chilean Typhoid Committee Large-scale field trial of Ty21a oral typhoid vaccine in enteric-coated capsule formulation. Eancet 1987a; i1049–1052
    [Google Scholar]
52. Levine M. M., Herrington D., Murphy J. R., Morriss J. G., Losonsky G., Tall B., Lindberg A., Svenson S., Baqar S., Edwards M. F., Si Stocker B. A. D. Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty as live oral vaccines in humans. J Clin Invest 1987b; 79888–902
    [Google Scholar]
53. Levine M. M., Kaper J. B., Herrington D., Losonsky G., Morris J. G., Clements M. L., Black R. E., Tall B., Hall R. Volunteer studies of deletion mutants of Vibrio cholerae Ol prepared by recombinant techniques. Infect Immun 1988; 56161–171
    [Google Scholar]
54. Lewis D. J. M., Novotny P., Dougan G., Griffin G. E. The early cellular and humoral immune response to primary and booster oral immunization with cholera toxin B-subunit in humans. Eur J Immunol 1991; 212087–2094
    [Google Scholar]
55. Lewis D. J. M., Castello-Branco L. R. R., Novotny P., Dougan G., Griffin G. E. Circulating cellular immune response to oral immunization of humans with cholera toxin B-subunit. Vaccine 1993; 11119–121
    [Google Scholar]
56. Lipscombe M., Charles I. G., Roberts M., Dougan G., Tite J., Fairweather N. F. Intranasal immunization using B subunit of the Escherichia coli heat labile toxin fused to an epitope of the Bordetella pertussis P69 antigen.. Mol Microbiol 1991; 51385–1392
    [Google Scholar]
57. Lycke N., Holgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986; 59301–308
    [Google Scholar]
58. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins are linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992; 222277–2281
    [Google Scholar]
59. McGhee J. R., Mestecky J., Dertzbaugh M. T., Eldridge J. H., Hirasawa M., Kiyono H. The mucosal immune system: from fundemental concepts to vaccine development. Vaccine 1992; 1075–81
    [Google Scholar]
60. Maghazachi A. A. Cholera toxin inhibits interleukin 2-induced, but enhances pertussis toxin-induced T-cell proliferation: regulation by cyclic nucleotides. Immunology 1992; 75103–106
    [Google Scholar]
61. Masked D. J., Sweeney K. J., O’Callaghan D., Hormaeche C. E., Liew F. Y., Dougan G. Salmonella typhimurium aroA mutants as carriers of the Escherichia coli heat-labile enterotoxin B subunit to the murine secretory and systemic immune systems. Microb Pathog 1987; 2211–221
    [Google Scholar]
62. Miller I. A., Chatfield S. N., Dougan G., DeSilva L., Joysey H., Hormaeche C. H. Bacteriophage P22 as a vehicle for transducing cosmid gene banks between smooth strains of Salmonella typhimurium: use in identifying a role for aroD in attenuating virulent Salmonella strains. Mol & Gen Genet 1989a; 215312–316
    [Google Scholar]
63. Miller I., Masked D., Hormaeche C., Johnson K., Dougan G. The isolation of orally attenuated Salmonella typhimurium following TnphoA mutagenesis. Infect Immun 1989b; 572758–2763
    [Google Scholar]
64. Miller S. I., Kukral A. M., Mekalanos J. J. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence in mice. Proc Natl Acad Sci USA 1989; 865054–5058
    [Google Scholar]
65. Minor P. The molecular biology of polio vaccines. J Gen Virol 1992; 733065–3077
    [Google Scholar]
66. Nakayama K., Kelley S. M., Curtiss R. III Construction of an asd expression-cloning vector: stable maintenance and high level expression of cloned genes in Salmonella based vaccine strains. Bio/ Technology 1988; 6693–697
    [Google Scholar]
67. O’Callaghan D., Masked D., Liew F. Y., Easmon C. S. F., Dougan G. Characterization of aromatic-dependent and purine-dependent Salmonella typhimurium:studies on attenution, persistence and ability to induce protective immunity in BALB/c mice. Infect Immun 1988; 56419–423
    [Google Scholar]
68. O’Callaghan D., Masked D., Tite J., Dougan G. Immune responses in BALB/c mice following immunization with aromatic compound or purine dependent Salmonella typhimurium strains. Immunology 1990; 69184–189
    [Google Scholar]
69. O’Goara P., Masked D., Coleman D., Cafferkey M., Dougan G. Cloning and sequence analysis of the serC, aroA genes of a Yersinia enterocolitica aroA mutant. Gene 1989; 8423–30
    [Google Scholar]
70. O’Hagan D. T. Novel non-replicating antigen delivery systems. Curr Opin Infect Dis 1990; 3393–401
    [Google Scholar]
71. Oxer M. D., Bentley C. M., Doyle J. G., Peakman T. C., Charles I. G., Makoff A. J. High level heterologous expression in E. coli using the anaerobically-activated nirB promoter. Nucleic Acids Rit 1991; 191889–1897
    [Google Scholar]
72. Peakman T., Crouzet J., Jayaux J. F., Busby S., Mohan S., Harborne N., Wooton J., Nicholson R., Cole J. Nucleotide sequence, organization and structural analysis of the products of genes in the nirR-cysB region of the Escherichia coli chromosome. Eur J Biochem 1990; 191315–324
    [Google Scholar]
73. Pittard A. J. Biosynthesis of the aromatic amino acids. In Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology 1990 Edited by Neidhardt F. C. ashington, DC: American Society for Microbiology; vol 1, pp368–390
    [Google Scholar]
74. Poirier T. P., Kehoe M., Beachey E. H. Protective immunity evoked by oral administration of attenuated aroA Salmonella typhimurium expressing streptococcal M protein. J Exp Med 1988; 16825–36
    [Google Scholar]
75. Reitman M. Infectivity and antigenicity of streptomycin- dependent Salmonella typhosa. J Infect Dis 1967; 17101–107
    [Google Scholar]
76. Reiman D., Tuomanen E., Falkow S., Golenbock T., Saukkonen K., Wright S. D. Recognition of a bacterial adhesin by an integrin: macrophage CR3 bind filamentous hemagglutinin of Bordetella pertussis. Cell 1990; 611375–1382
    [Google Scholar]
77. Roberts M., Masked D., Novotny P., Dougan G. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infect Immun 1989; 58732–739
    [Google Scholar]
78. Roberts M., Cropley I., Chatfield S., Dougan G. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. Vaccine 1993; 11866–872
    [Google Scholar]
79. Sadoff J. C., Ballou R. W., Baron L. S., Marjaran W. R., Brey R. N., Hockmeyer W. T., Young J., Cryz J. J., Ou J., Lowed G. H., Chulay J. D. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988; 240236–240
    [Google Scholar]
80. Sandros J., Tuomanan E. Attachment factors of Bordetella pertussis-, mimicry of eucaryotic cell recognition molecules. Trends Microbiol 1993; 1192–195
    [Google Scholar]
81. Schodel F., Enders G., Jung M. C., Will H. Recognition of a hepatitis B virus nucleocapsid T-cell epitope expressed as a fusion protein with the B subunit of Escherichia coli heat-labile in attenuated Salmonella. Vaccine 1990; 8569–575
    [Google Scholar]
82. Servos S., Chatfield S. N., Hone D., Levine M., Dimitriadis G., Pickard D., Dougan G., Fairweather N. F., Charles I. Molecular cloning and characterization of the aroD gene encoding 3-dehydroquinase from Salmonella typhi. J Gen Microbiol 1991; 137147–152
    [Google Scholar]
83. Shahin R. D., Amsbaugh D. F., Leef M. F. Mucosal immunization with filamentous haemagglutinin protects against Bordetella pertussis respiratory tract infection. Infect Immun 1992; 601482–1488
    [Google Scholar]
84. Sixma T. K., Pronk S. E., Kalk K. H., Wartna E. S., Van Zanten B. A. M., , Witholt B., Hol W. G. J. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E coli.. Nature 1991; 351371–376
    [Google Scholar]
85. Strahan K., Chatfield S. N., Tite J., Dougan G., Hormaeche C. E. Impaired resistance to infection does not increase the virulence of Salmonella htrA live vaccines in mice. Microb Pathog 1992; 12311–317
    [Google Scholar]
86. Strugnell R., Masked D., Fairweather N., Pickard D., Cockayne A., Penn C., Dougan G. Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains. Gene 1990; 8857–63
    [Google Scholar]
87. Strugnell R., Dougan G., Chatfield S. N., Charles I., Fairweather N. F., Tite J., Li Jing Li, Beesely J., Roberts M. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P. 69 antigen of Bordetella pertussis. Infect Immun 1992; 603994–4002
    [Google Scholar]
88. Svennerholm A, -M., Holmgren 1. Oral combined B subunit-whole cell cholera vaccine. In Development of Vaccines and Drugs Against Diarrhoea, 1lth Nobel Conference, Stockholm, 1985 1986 Edited by Holmgren J., Lindberg A., Mollby R. Lund: Student-lituratur;33–43
    [Google Scholar]
89. Tacket C. O., Hone D. M., Losonsky G. A., Guers L., Adelman R., Levine M. M. Clinical acceptability and immunogenicity of CYD908 Salmonella typhi vaccine strain. Vaccine 1992a; 10443–446
    [Google Scholar]
90. Tacket C. O., Hone D. M., Curtiss R. III, Kelly S. M., Losonsky G., Guers L., Harris A. M., Edelman R., Levine M. M. Comparison of the safety and immunogenicity of delta aroC, delta aro A and delta cya, delta crp Salmonella typhi strains in adult volunteers. Infect Immun 1992b; 60536–544
    [Google Scholar]
91. Tite J. P., Russell S. M., Dougan G., O’Callaghan D., Jones I., Brownlee G., Liew F. Y. Antiviral immunity induced by recombinant nucleoprotein of influenzae A virus. I. Characteristics and cross-reactivity of T-cell responses. J Immunol 1988; 1413980–3987
    [Google Scholar]
92. Tite J. P., Gao Y. M., Hughes-Jenkins C. M., Lipscombe M., O’Callaghan D., Dougan G., Liew F. Y. Anti-viral immunity induced by recombinant nucleoprotein of influenzae A virus III. Delivery of recombinant nucleoprotein to the immune system using attenuated Salmonella typhimurium as a live carrier.. Immunology 1990; 70540–546
    [Google Scholar]
93. Waderman M. H., Serie C., Cerisier Y., Sallam S., Germanier R. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid; three year results. J Infect Dis 1982; 145292–295
    [Google Scholar]
94. Wilson A. D., Robinson A., Irons L., Stokes C. R. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody responses to orally administered antigen. Vaccine 1993; 11113–118
    [Google Scholar]
95. Wu H.-Y., Russell M. W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun 1993; 61314–322
    [Google Scholar]